Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116750 | 0.99 | ROCK2 (0.46) | ROCK2MEN1KMT2AL3MBTL1OPRL1 | |
| SCHEMBL118485 | 0.97 | ROCK2 (0.46) | ROCK2MEN1KMT2AL3MBTL1OPRL1 | |
| SCHEMBL566537 | 0.91 | ROCK2 (0.44) | ROCK2MEN1KMT2AL3MBTL1TP53 | |
| SCHEMBL175520 | 0.89 | QRFPR (0.57) | ROCK2MEN1KMT2AL3MBTL1CYP2D6 | |
| SCHEMBL566626 | 0.85 | ROCK2 (0.59) | ROCK2MEN1KMT2AL3MBTL1TP53 | |
| SCHEMBL117608 | 0.82 | ROCK2 (0.48) | ROCK2MEN1KMT2AL3MBTL1TP53 | |
| SCHEMBL168400 | 0.78 | ESR2 (0.50) | ROCK2MEN1KMT2AL3MBTL1TP53 | |
| SCHEMBL167070 | 0.76 | MEN1 (0.49) | ROCK2MEN1KMT2AL3MBTL1TP53 | |
| SCHEMBL4771567 | 0.76 | ROCK2 (0.46) | ROCK2MEN1KMT2ATP53RXFP1 | |
| SCHEMBL14072506 | 0.74 | ROCK2 (0.49) | ROCK2MEN1KMT2AL3MBTL1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424861-A1 | INDOLE-2-CARBOXAMIDE DERIVATIVE | MSD K.K. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120035155-A1 | INDOLE-2-CARBOXAMIDE DEIVATIVE | MSD K.K. (JP) | 2012-02-09 | — | — | US | disclosed |
| WO-2010126164-A1 | INDOLE-2-CARBOXAMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035155-A1 | INDOLE-2-CARBOXAMIDE DEIVATIVE | HTR1F, HTR3C, HTR6 | ROCK2 1387/4885MEN1 2469/4885KMT2A 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.